Entrada Therapeutics (TRDA) Insider Trading & Ownership $8.31 -0.49 (-5.57%) As of 12:46 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Entrada Therapeutics (NASDAQ:TRDA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage7.59%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$67,237.04Number OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$1.29 M Get TRDA Insider Trade Alerts Want to know when executives and insiders are buying or selling Entrada Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address TRDA Insider Buying and Selling by Quarter Remove Ads Entrada Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/10/2024Bioventures 2018 L.P. MpmMajor ShareholderSell22,935$20.77$476,359.95 12/2/2024Kory James WentworthCFOSell5,000$20.00$100,000.00 11/29/2024Kory James WentworthCFOSell1,000$19.97$19,970.00 11/13/2024Natarajan SethuramanInsiderSell2,700$20.04$54,108.00 11/11/2024Kory James WentworthCFOSell8,637$19.98$172,567.26 11/11/2024Natarajan SethuramanInsiderSell1,409$20.01$28,194.09 10/16/2024Natarajan SethuramanInsiderSell600$18.00$10,800.00 9/26/2024Nathan J DowdenCOOSell847$16.00$13,552.00 9/9/2024Kory James WentworthCFOSell3,195$14.97$47,829.15 9/9/2024Natarajan SethuramanInsiderSell2,642$15.09$39,867.78 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 9/9/2024Nathan J DowdenCOOSell1,904$15.07$28,693.28 9/6/2024Natarajan SethuramanInsiderSell600$15.24$9,144.00 9/6/2024Nathan J DowdenCOOSell399$15.19$6,060.81 7/15/2024Dipal DoshiCEOSell1,600$17.81$28,496.00 7/15/2024Natarajan SethuramanInsiderSell638$18.00$11,484.00 7/12/2024Dipal DoshiCEOSell300$18.00$5,400.00 7/12/2024Natarajan SethuramanInsiderSell600$18.00$10,800.00 7/8/2024Kory James WentworthCFOSell1,758$14.95$26,282.10 6/13/2024Dipal DoshiCEOSell1,000$16.17$16,170.00 5/20/2024Natarajan SethuramanInsiderSell9,675$15.19$146,963.25 5/16/2024Dipal DoshiCEOSell1,800$15.00$27,000.00 5/16/2024Natarajan SethuramanInsiderSell1,000$15.00$15,000.00 5/8/2024Peter S KimDirectorBuy2,276$14.04$31,955.04 4/8/2024Peter S KimDirectorBuy2,600$13.57$35,282.00 (Data available from 1/1/2013 forward) TRDA Insider Trading Activity - Frequently Asked Questions Who is on Entrada Therapeutics's Insider Roster? The list of insiders at Entrada Therapeutics includes Bioventures 2018 L.P. Mpm, Bros. Advisors Lp Baker, Dipal Doshi, Kory James Wentworth, Natarajan Sethuraman, Nathan J Dowden, Nerissa Kreher, and Peter S Kim. Learn more on insiders at TRDA. What percentage of Entrada Therapeutics stock is owned by insiders? 7.59% of Entrada Therapeutics stock is owned by insiders. Learn more on TRDA's insider holdings. Which Entrada Therapeutics insiders have been buying company stock? The following insider purchased TRDA shares in the last 24 months: Peter S Kim ($151,226.80). How much insider buying is happening at Entrada Therapeutics? Insiders have purchased a total of 11,172 TRDA shares in the last 24 months for a total of $151,226.80 bought. Which Entrada Therapeutics insiders have been selling company stock? The following insiders have sold TRDA shares in the last 24 months: Bioventures 2018 L.P. Mpm ($476,359.95), Dipal Doshi ($250,052.92), Kory James Wentworth ($873,740.63), Natarajan Sethuraman ($452,127.12), Nathan J Dowden ($365,434.77), and Nerissa Kreher ($266,748.00). How much insider selling is happening at Entrada Therapeutics? Insiders have sold a total of 159,244 Entrada Therapeutics shares in the last 24 months for a total of $2,684,463.39 sold. Entrada Therapeutics Key ExecutivesMr. Dipal Doshi (Age 48)CEO & Director Compensation: $968.21kMr. Nathan J. Dowden (Age 53)President & COO Compensation: $694.3kDr. Natarajan Sethuraman Ph.D. (Age 62)Chief Scientific Officer Compensation: $694.3kMr. Kory James Wentworth CPA (Age 45)CFO & Treasurer 3 recent tradesDr. Jared Cohen J.D.Ph.D., General CounselMs. Kerry Robert M.S.Senior Vice President of PeopleMs. Karla MacDonaldChief Corporate Affairs OfficerMr. Kevin Healy Ph.D.Senior Vice President of Regulatory Affairs More Insider Trading Tools from MarketBeat Related Companies Dyne Therapeutics Insider Trades Wave Life Sciences Insider Trades ARS Pharmaceuticals Insider Trades Ardelyx Insider Trades Ocular Therapeutix Insider Trades Structure Therapeutics Insider Trades Aurinia Pharmaceuticals Insider Trades Adaptive Biotechnologies Insider Trades Iovance Biotherapeutics Insider Trades 89bio Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Casey’s General Stores Insider Buys Shares of This Must-Own StockNVIDIA Insiders Sell: This Is What It Means for the Market Top 3 Insider Stock Buys in March—Are They Still Good in April?Grocery Outlet Insider and Institutional Buyers Signal BottomSentinelOne Insider Selling? Why Investors Should Stay Bullish This page (NASDAQ:TRDA) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TRDA Stock Free TRDA Stock Alerts